Alpha Tau Medical, a Nasdaq-listed company specializing in tumor treatment, announced on Thursday that it will present an abstract featuring clinical results of its Alpha Diffusing Alpha-emitters Radiation Therapy (DaRT) technology for pancreatic cancer at the upcoming Digestive Disease Week® (DDW) 2026 in the U.S.
This presentation, based on two clinical trials conducted in Jerusalem, marks the first time Alpha DaRT’s pancreatic cancer clinical outcomes will be showcased at a major international gastroenterology conference.
DDW is the world’s largest gathering of experts in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. This year’s event is scheduled to take place in Chicago from May 2 to May 5.
Alpha Tau’s presentation is titled, Updated Results on Feasibility, Safety, and Tumor Control Confirmed in Two Human Clinical Trials of a Novel Alpha-emitting Radionuclide for Pancreatic Cancer.
Uzi Sofer, Chief Executive Officer (CEO) of Alpha Tau, emphasized the significance of this presentation, stating that this is a crucial milestone for the company. Considering that most pancreatic cancer patients are diagnosed when surgery is no longer an option, it believes Alpha DaRT could offer a groundbreaking treatment approach for both locally advanced and metastatic cases.
